Eric Chen runs the smallest big Layer-1 in crypto, and in the last two weeks his bet has started to pay. On May 7, Circle launched native USDC and CCTP on Injective, ending years of bridged-stablecoin friction on a chain built explicitly for finance. The day before that, the monthly Community BuyBack burned more than 55,000 INJ with record participation, and the 21Shares spot INJ ETF filing is still sitting with the SEC alongside live regulated INJ futures on a US venue. The man behind all of it is 30-something, MIT-trained, and almost never quoted on CNBC.
Chen is the co-founder and CEO of Injective Labs and one of the two original architects of a chain that has spent six years trying to do one thing well. The thing is on-chain derivatives at the speed and finality of a centralized exchange. That is a sentence every L1 has said at some point. Injective is one of the few that built the order book into the protocol itself.
The 2018 Bet on a Derivatives-Native Layer 1
Chen co-founded Injective Protocol in 2018 with Albert Chon, a Stanford computer-science alum who had spent time at Amazon Web Services. Chen himself studied at NYU Stern and spent his pre-Injective years on the venture and trading side, including a stint at Innovating Capital where he ran fundamental analysis on early-stage protocols. Chon brought the protocol-engineering background and Chen brought the markets-structure instinct, and the two spent 2018 sketching out what an L1 built for derivatives would actually need to do differently.
The crypto market in 2018 looked nothing like it does in 2026. Ethereum was the only credible smart-contract chain at scale, DeFi as a category did not exist yet, and decentralized derivatives meant 0x order-book demos that nobody actually traded on. Chen and Chon went the opposite direction from the crowd. They picked one vertical, on-chain derivatives, and asked what an entire chain would look like if every architectural decision was made in service of that single use case.
The answer was a chain with a native order-book module at the protocol level, sub-second block times, MEV-resistant batch auctions, and a derivatives settlement layer that did not depend on bolting an AMM onto a general-purpose VM. It was a contrarian call in a market that mostly believed AMMs would eat order books forever. The pair pitched aggressively anyway.
Y Combinator, Binance Labs, and the Cosmos Build
The validation came faster than most founders get it. Injective went through Y Combinator's Winter 2018 batch, the first crypto exchange protocol YC ever accepted, and Binance Labs then incubated the project as one of its very first portfolio companies. That slot came with engineering resources and exchange-integration access that almost no early-stage DeFi team had at the time. Pantera Capital, Hashed, and Jump Crypto eventually followed, but the YC plus Binance Labs combination is what gave Chen the runway to do the long technical work without raising every six months.
That long technical work landed on Cosmos. Injective shipped mainnet in November 2021 as a sovereign Cosmos-SDK Layer 1 with its own validator set, Tendermint-based consensus, and finality measured in single digits of seconds rather than minutes. Picking Cosmos over rolling their own L1 from scratch saved roughly two years of consensus work, and made interoperability with the rest of the Cosmos ecosystem free out of the box via IBC.
The Cosmos-SDK choice was contested inside crypto Twitter for a long time. Critics argued Cosmos chains would never get the developer mindshare or stablecoin liquidity that EVM chains attract. Chen kept pointing at the same answer. A chain built for derivatives needs deterministic finality, predictable block times, and a customizable execution environment, and Cosmos delivers all three in a way that EVM-on-rollup setups still struggle with in 2026.
What Injective Actually Shipped
The deliverables list is more concrete than most L1 marketing decks. The native on-chain order book has been live since mainnet, used today by Helix, the largest perpetuals venue on Injective, and a handful of options and prediction-market protocols built directly on top of the module. Frequent batch auctions execute every block to neutralize the front-running and sandwich-attack patterns that bleed AMM-based DEX users on other chains. CosmWasm smart contracts have been live since 2022 for the Rust developer base that Cosmos attracts.
The MultiVM track is the bigger story for 2026 and the part Chen has talked about most publicly. Injective now supports CosmWasm, an EVM execution environment, and a Solana Virtual Machine layer that the team has been building toward across multiple testnet phases. The pitch is simple. A developer who has already written a perpetuals contract in Solidity or Rust should be able to deploy on Injective with no rewrite and tap the native order book through a precompile. The question of how well MultiVM lives up to that pitch in practice is still being tested by the developers actually porting code over, but the architectural bet is unusual.
Cross-chain bridging is the third leg. Injective's Peggy bridge has moved Ethereum-based assets onto the chain since the start, and IBC connects the Cosmos side. The Circle native USDC and CCTP launch on May 7 closes the last meaningful gap, because for the first time stablecoin flows in and out of Injective do not require a wrapped-asset detour through Ethereum.
The May 2026 Catalyst Stack
Most of what is moving INJ right now landed in the first half of May, and it landed in clusters rather than as a single headline.
Circle native USDC and CCTP on Injective, May 7. The single most important plumbing upgrade Injective has shipped in the last year. Native USDC and CCTP v2 mean stablecoins on Injective are now interchangeable one-for-one with USDC on Ethereum, Solana, Base, and every other chain Circle supports, with no bridge risk and no liquidity fragmentation.
May 6 Community BuyBack burned 55,000+ INJ. The monthly buyback mechanism takes 60% of dApp fees on Injective, swaps them for INJ on the open market, and burns them. The May edition cleared its largest participation total since launch, and the cumulative burn now sits in the millions of INJ retired from circulation. That supply pressure only shows up in price action if demand keeps pace, and the mechanism itself is one of the more honest buyback designs in crypto because the inputs are verifiable on-chain.
21Shares INJ ETF filing. 21Shares filed for a spot INJ ETF earlier this year and the application is still under review with the SEC. If approved alongside the broader wave of spot altcoin ETF filings, it would put INJ in a very small group of L1 tokens with regulated US exposure.
Regulated INJ futures live on a US venue. Coinbase launched regulated INJ perpetual futures earlier in 2026 and the contracts have been quietly building open interest since launch. The signal matters more than the contract itself, because a major US-licensed venue listing INJ tells you something about how regulators are reading the token.
Each of these on its own would be a one-day headline. Stacked together inside a single month, they form the strongest fundamental setup INJ has had since the post-2021 cycle peak.
What Chen Is Shipping Next, and Where the Bet Could Still Fail
The next leg of the Injective roadmap is mostly about turning architectural bets into developer activity. The EVM and SVM execution layers need real applications deployed on them, beyond simple port-overs from teams looking for grant money. The native order book needs deeper non-perp use cases, things like RWA settlement, on-chain options venues, and prediction markets that actually clear meaningful volume. INJ needs to absorb the buyback supply pressure into sustained price strength rather than burn into a market that does not care.
The risks are real. Hyperliquid runs the largest perpetuals DEX in the market right now and has been pulling order flow from every L1 with on-chain derivatives ambitions, Injective included. Solana has the consumer attention and the deeper stablecoin float. Ethereum still hosts the institutional treasuries. A chain built specifically for derivatives has to win on the merits of its execution environment, and so far the volume gap between Helix on Injective and Hyperliquid is the part of the picture INJ bulls would prefer not to discuss.
The ETF approval is also not guaranteed. The SEC has approved spot BTC and ETH products and signaled openness to a Solana product, but the bar for an INJ-scale altcoin is higher and the political clock is uncertain. A stalled or denied 21Shares filing removes one of the cleaner catalysts on the calendar.
And Chen himself is a quieter founder than most of the L1 CEOs he competes with. He does podcast appearances and talks at industry events, but he is not Anatoly Yakovenko on Twitter or Vitalik Buterin at Devcon. For a token that competes for institutional mindshare, the founder's public presence matters at the margin. His low-key style reads as an asset to builders who respect the focus, and as a liability to the retail flow that sometimes does not notice the chain exists at all.
Frequently Asked Questions
Is Eric Chen still the CEO of Injective Labs?
Yes. Chen has been CEO since co-founding the company with Albert Chon in 2018 and remains the public face of the project. Chon has stepped back from a day-to-day operating role over time, with Chen running both the protocol direction and the institutional relationships.
How much INJ does Eric Chen own?
Specific founder holdings for Chen have never been disclosed publicly, and Injective Labs has never released a wallet breakdown. The initial token distribution allocated a percentage to the founding team and Injective Labs with multi-year vesting schedules that have largely completed by 2026. Chen has acknowledged in interviews that he holds INJ but has not shared a wallet address or figure.
Why did Injective pick Cosmos instead of building on Ethereum?
Chen has repeatedly pointed at deterministic finality, sub-second blocks, and the freedom to ship a native order-book module at the protocol level. None of those were available on Ethereum mainnet in 2018, and they are still hard to replicate cleanly on EVM rollups in 2026. Cosmos let Injective customize the execution environment for derivatives without burning years building a consensus engine from scratch.
What is the biggest risk to Injective under Chen?
Competition from Hyperliquid for perp DEX flow and from broader EVM rollups for general derivatives infrastructure. Injective's architectural edge is real, but architectural edges do not always translate into liquidity if developers and traders concentrate elsewhere. The honest answer is that the next twelve months of MultiVM developer adoption and the 21Shares ETF outcome will tell you if the bet works.
Bottom Line
Chen is the rare crypto founder whose chain looks better in 2026 than it has at any point in its six-year history, and the catalyst stack is unusually clean. Native USDC closes the stablecoin gap, the buyback mechanism continues to retire INJ supply on a verifiable schedule, the 21Shares ETF filing offers a regulatory upside surprise, and the MultiVM rollout gives the developer base a real reason to deploy. Watch three things over the next two quarters. The pace of EVM and SVM application launches on Injective, the SEC's posture on the spot INJ ETF, and the question of how well Helix can hold or grow its share of on-chain perp volume against Hyperliquid. If two of those break in Chen's favor, the bet he made in 2018 starts to look obvious in hindsight. If all three slip, INJ goes back to being a small L1 with an interesting architecture and a quiet founder. The next two quarters decide which version the market gets.
This article is for informational purposes only and does not constitute financial or investment advice. Cryptocurrency trading involves substantial risk. Always conduct your own research before making trading decisions.
